Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

NCT04756765 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Due to changes in the treatment landscape, the study faced significant recruitment challenges. As no patients were enrolled, the sponsor requested study closure

Conditions

Interventions

Sponsor

Stanford University

Collaborators